Cytovale

Cytovale is committed to improving patient care by pioneering early detection technologies that assess immune activation to accelerate the time it takes to get from triage to life-saving therapies. Cytovale is based in San Francisco and venture-backed by Norwest Venture Partners, Sands Capital, Global Health Investment Corporation (GHIC), CPP Investments, Breakout Ventures and other leading investors. For more information, visit www.cytovale.com and follow Cytovale on LinkedIn and X.

Content by Cytovale

Filter by

All Article Audio Document Event Infographic Survey Video

The findings suggest that leveraging IntelliSep to enable early sepsis detection can drive repeatable patient-centered outcomes in diverse ED settings.

|2 min read

Multicenter Study of IntelliSep Shows 19% Reduction in Sepsis Mortality

The findings report double-digit operational improvements across four hospitals

byCytovale

Illustration of two clinical lab professionals wearing white PPE holding a giant magnifying glass over the word "sepsis."

|2 min read

Cytovale Completes $100 Million Series D Funding to Accelerate Commercial Expansion of Its Rapid Sepsis Solution

IntelliSep is the first and only FDA-cleared cellular host diagnostic indicated for use in the ED

byCytovale

Page 1 of 1

Cytovale

Content by Cytovale

Multicenter Study of IntelliSep Shows 19% Reduction in Sepsis Mortality

Cytovale Completes $100 Million Series D Funding to Accelerate Commercial Expansion of Its Rapid Sepsis Solution

Sponsored

When the Sample Waits: Pre-Analytical Variability in Multi-Analyte Blood Testing

Protecting Clinical Lab Uptime

Lessons Learned from a Successful Digital Pathology Deployment at CorePath Laboratories

Preserving Sample Integrity When Processing is Delayed